Patients with LUSC (TCGA-LUSC.htseq_counts.tsv) showing high expression of GFPT2 exhibited lower overall survival (P < 0.05) than those with low expression (Fig. 7D), suggesting that GFPT2+ fibroblasts may be associated with poor survival in patients with NSCLC. This evidence concerns the gene GFPT2 and non-small cell lung carcinoma.